Tobacco: The 8 Million Annual Deaths WHO Calls “One of the Biggest Public Health Threats Ever”

KEY FACTS

• Tobacco kills over 8 million people annually worldwide—more than 7 million from direct use and 1.3 million non-smokers from secondhand smoke exposure
• Around 80% of the world’s 1.25 billion tobacco users live in low- and middle-income countries, where the burden of tobacco-related illness and death falls heaviest
• Globally, roughly one in five adults uses tobacco in 2022, down from one in three in 2000, representing significant but insufficient progress toward WHO’s reduction targets
• Only 56 countries are on track to achieve WHO’s 30% relative reduction in tobacco use by 2025, down from 60 countries in the previous report three years ago
• The WHO Framework Convention on Tobacco Control, adopted in 2003 and ratified by 182 countries covering over 90% of the world’s population, remains the fastest-adopted treaty in UN history

Every four seconds, someone in the world dies from tobacco use or exposure to secondhand smoke. That’s 22,000 avoidable deaths every single day—8 million every year. Yet despite this catastrophic toll, six countries saw tobacco use rates rise between reports: Congo, Egypt, Indonesia, Jordan, Oman, and Moldova.

WHO’s January 2024 global report on tobacco trends delivered mixed news to global health initiatives tracking the epidemic. Yes, prevalence continues declining in 150 countries. Brazil achieved a remarkable 35% relative reduction since 2010 through comprehensive implementation of evidence-based policies. The Netherlands nears its 30% target. But overall progress has stalled—the world won’t hit the voluntary 30% reduction goal by 2025, settling instead for roughly 25%.

What’s blocking faster progress? WHO points directly at tobacco industry interference. Companies spent over $8 billion on marketing and advertising, deploying what economists call “the economics of deception and manipulation” to recruit new users—particularly targeting youth in low- and middle-income countries where regulation remains weak. The industry produces and promotes a product scientifically proven to be addictive, to cause disease and death, and to perpetuate poverty by diverting household spending from basic needs.

This article examines WHO’s data on the tobacco epidemic, investigates why some countries succeed in reducing use while others fail, and asks whether the Framework Convention on Tobacco Control—despite becoming one of history’s most widely ratified treaties—possesses sufficient enforcement mechanisms to protect billions from an entirely preventable cause of death and disability.

What Is Tobacco? — WHO’s Definition

According to WHO, tobacco encompasses all products prepared entirely or partly from the tobacco plant leaf (Nicotiana tabacum) that are manufactured to be used for smoking, sucking, chewing, or snuffing. The organization emphasizes a critical point: all forms of tobacco are harmful, and there is no safe level of exposure to tobacco smoke.

WHO categorizes multiple product types under the tobacco umbrella. Cigarette smoking represents the most common form of tobacco use worldwide. But the organization documents a diverse array of other products: waterpipe tobacco (hookah or shisha), cigars and cigarillos, heated tobacco products, roll-your-own tobacco, pipe tobacco, bidis and kreteks (popular in Southeast Asia), and smokeless tobacco products including chewing tobacco and snuff.

The organization’s framework identifies heated tobacco products (HTPs) as a category requiring particular attention. These devices heat tobacco (rather than burning it) to produce aerosols containing nicotine and toxic chemicals. WHO reports that HTPs contain the highly addictive substance nicotine, non-tobacco additives, and are often flavoured—characteristics designed to appeal to new users, particularly youth.

All tobacco products share a common mechanism of harm: they deliver nicotine—a highly addictive psychoactive drug—alongside thousands of chemicals, many of which cause cancer, cardiovascular disease, and respiratory illness. WHO reports that tobacco use contributes to poverty by diverting household spending from basic necessities like food and shelter to an addictive product. This spending pattern proves difficult to curb precisely because nicotine dependence is so powerful.

WHO also addresses electronic nicotine delivery systems (ENDS), commonly called e-cigarettes or vapes. While these products don’t contain tobacco leaf, the organization includes them in tobacco control frameworks because they deliver nicotine and often serve as gateway products to combustible tobacco use. Research shows that children and adolescents who use e-cigarettes at least double their chances of smoking cigarettes later in life.

Global Burden — WHO’s Epidemiological Data

The scale of tobacco’s human and economic devastation is staggering. WHO reports that tobacco kills over 8 million people annually—equivalent to the entire population of New York City dying every single year from a completely preventable cause. More than 7 million of these deaths result from direct tobacco use, while approximately 1.3 million non-smokers die from exposure to secondhand smoke.

Global surveillance data compiled by CDC confirms that tobacco-related illnesses cost the global economy $1.4 trillion annually—roughly 1.8% of the world’s GDP in 2012. This economic burden falls disproportionately on countries least able to afford it.

Current user numbers tell a troubling story about where the epidemic concentrates. WHO’s January 2024 trends report found that globally, 1.25 billion people use tobacco. Around 80% of these users—approximately 1 billion people—live in low- and middle-income countries, where healthcare systems struggle to manage tobacco-attributable diseases and where prevention resources remain scarce.

Regional disparities reveal striking patterns. According to UN News coverage of WHO’s 2024 report, Southeast Asia currently has the highest percentage of population using tobacco at 26.5%, followed closely by Europe at 25.3%. Europe presents a particularly troubling gender pattern—tobacco use rates among women in Europe are more than double the global average and are reducing much slower than in all other regions.

The prevalence trajectory shows both progress and stagnation. In 2022, roughly one in five adults worldwide used tobacco, down from one in three in 2000. This represents significant absolute progress—hundreds of millions fewer users than two decades ago. But the rate of decline has slowed considerably. WHO’s analysis shows the world is on track to achieve only a 25% relative reduction in tobacco use by 2025, falling short of the voluntary global target of 30% reduction from the 2010 baseline.

Country-level performance varies enormously. WHO data analyzed in the 2024 global report found that 150 countries are successfully reducing tobacco use rates among people aged 15 and above. Brazil exemplifies what comprehensive policy implementation can achieve—a 35% relative reduction since 2010. The Netherlands sits on the verge of reaching the 30% target.

But six countries are moving in the wrong direction, with tobacco use rates rising: Congo, Egypt, Indonesia, Jordan, Oman, and Moldova. WHO attributes these increases to insufficient tobacco control policies, aggressive industry marketing, and weak enforcement of existing regulations.

Age-specific patterns reveal the importance of preventing youth initiation. WHO emphasizes that most smokers start before age 18, and nearly all begin before age 25. Once nicotine addiction establishes during adolescence, quitting becomes exponentially harder. The organization’s data shows that protecting youth from tobacco marketing and access represents one of the most cost-effective interventions for reducing future disease burden.

Disease-specific mortality reveals tobacco’s broad pathological impact. PAHO data on tobacco control shows that in the Americas, mortality from tobacco use accounts for 15% of deaths from cardiovascular disease, 24% of cancer deaths, and 45% of chronic respiratory disease deaths. Tobacco stands as a risk factor for multiple specific conditions: lung cancer, chronic obstructive pulmonary disease, ischemic heart disease, stroke, diabetes, and numerous other cancers including those of the mouth, throat, esophagus, stomach, liver, kidney, and bladder.

Research published in Our World in Data analyzing Institute for Health Metrics and Evaluation estimates found that 8.7 million people died prematurely from tobacco use in 2019. Of these, 7.7 million resulted from smoking while 1.3 million were non-smokers dying from secondhand smoke exposure. An additional 56,000 people died from chewing tobacco. The data reveals that most (71%) of those dying prematurely from smoking are men—though this gender gap is narrowing as tobacco companies increasingly target women in developing markets.

The burden extends beyond mortality to years lived with disability. WHO reports that millions live in poor health because of tobacco-related chronic diseases: emphysema leaving people gasping for breath, cardiovascular disease causing repeated hospitalizations, cancers requiring grueling treatments with uncertain outcomes. For the entire 20th century, an estimated 100 million people died prematurely because of smoking—most in rich countries where the epidemic peaked earliest. This mirrors historical patterns of infectious disease burdens shifting from wealthy to poor nations, similar to challenges documented in ongoing efforts to control growth in various industrial sectors while managing public health impacts.

Causes, Transmission & Risk Factors — WHO’s Framework

WHO’s causal framework for tobacco addiction centers on nicotine—a powerful psychoactive substance that hijacks brain reward pathways. The organization reports that nicotine acts on nicotinic acetylcholine receptors in the central nervous system, triggering dopamine release that creates pleasurable sensations. With repeated exposure, the brain adapts by reducing receptor sensitivity and increasing receptor numbers, creating tolerance that drives users to consume more tobacco to achieve the same effects.

The biological mechanism of addiction develops rapidly, particularly in adolescent brains still undergoing development. WHO notes that youth are especially vulnerable to nicotine dependence—adolescents can become addicted after smoking just a few cigarettes. This explains why tobacco companies invest heavily in marketing to young people: early initiation creates lifetime customers.

Unlike infectious diseases that spread through biological transmission, tobacco “transmission” operates through social, economic, and marketing mechanisms. WHO documents several pathways through which tobacco use perpetuates:

Familial patterns show strong influence. Children of smokers are significantly more likely to start smoking themselves, through both modeling of behavior and access to cigarettes in the home. Secondhand smoke exposure in childhood also normalizes smoking and may create physiological changes that increase future susceptibility.

Peer influences drive adolescent initiation. WHO reports that social acceptance of smoking within peer groups, seeing friends smoke, and peer pressure all increase the likelihood of tobacco use. Social media has amplified these effects, with tobacco imagery and influencer marketing reaching youth despite advertising restrictions.

Marketing and advertising represent deliberately engineered risk factors. The tobacco industry spends over $8 billion annually on marketing, using sophisticated techniques to glamorize smoking, associate products with desirable lifestyles, and target specific demographic groups. Research on tobacco industry strategies reveals decades of documented deception about health risks and calculated efforts to recruit replacement smokers as existing users die or quit.

Socioeconomic factors create systematic vulnerability. WHO data shows that tobacco use rates are highest among people with lower education and income levels. The organization identifies several mechanisms: tobacco marketing deliberately targets disadvantaged communities, stress associated with poverty may drive tobacco use as a coping mechanism, and limited access to cessation resources perpetuates use despite desire to quit.

Product design features engineered to enhance addictiveness represent what WHO calls industry interference with public health. Tobacco companies add ammonia compounds that increase nicotine absorption, incorporate menthol and other flavors to mask harshness and appeal to young users, design cigarettes to deliver nicotine more efficiently to the brain, and include additives that make smoke easier to inhale. These design manipulations aren’t accidental—they’re the result of decades of industry research aimed at maximizing addiction.

Accessibility and affordability drive use patterns. WHO emphasizes that tobacco price represents the single most effective determinant of consumption—higher prices reduce use, particularly among youth and low-income users who are most price-sensitive. Conversely, cheap, easily available tobacco perpetuates the epidemic.

Cultural and social norms shape use in ways that transcend individual choice. In countries where smoking is socially acceptable or even expected in certain contexts (business meetings, social gatherings), initiation rates remain high. WHO notes that changing these norms requires comprehensive approaches including mass media campaigns, smoke-free policies, and de-normalization of tobacco use.

Policy and regulatory environments either protect populations or enable industry exploitation. Countries with weak tobacco control policies—no advertising bans, no smoke-free laws, minimal taxation, no package warnings—see higher use rates. WHO documents that industry interference in policy-making represents a fundamental conflict of interest: tobacco companies profit from addiction, disease, and death, creating irreconcilable opposition to public health goals.

Signs, Symptoms or Health Impacts — WHO’s Health Framework

WHO identifies tobacco use as a risk factor for six of the eight leading causes of death worldwide: ischemic heart disease, stroke, chronic obstructive pulmonary disease, diabetes, trachea/bronchus/lung cancers, and tuberculosis. The organization emphasizes that tobacco doesn’t cause just one disease—it systematically damages nearly every organ system.

Cardiovascular impacts emerge as the leading cause of tobacco-related death. WHO reports that smoking damages blood vessel walls, promotes atherosclerotic plaque formation, increases blood clotting tendency, reduces oxygen-carrying capacity of blood, and triggers cardiac arrhythmias. These mechanisms translate into clinical outcomes: heart attacks, strokes, peripheral vascular disease, and sudden cardiac death. The organization notes that smoking even a few cigarettes daily significantly increases cardiovascular risk—there is no safe level of tobacco exposure.

Respiratory diseases represent the most visible tobacco harm. WHO documents that smoking causes chronic bronchitis (persistent cough and sputum production), emphysema (progressive lung tissue destruction causing breathlessness), and chronic obstructive pulmonary disease (COPD)—a progressive, irreversible condition that ranks among the leading causes of death globally. Smokers also suffer increased frequency and severity of respiratory infections, asthma exacerbations, and pneumonia.

Cancer causation links tobacco to at least 15 different cancer types. WHO reports strong evidence for tobacco causing cancers of the lung, mouth, throat, voice box, esophagus, stomach, pancreas, liver, kidney, bladder, cervix, colon, and acute myeloid leukemia. Lung cancer exemplifies the devastating impact—about 90% of lung cancer cases are attributable to smoking. The organization notes that tobacco smoke contains over 70 known carcinogens that damage DNA, inhibit DNA repair, suppress immune surveillance of cancer cells, and promote tumor growth.

Reproductive and pregnancy impacts affect both mothers and infants. WHO identifies smoking during pregnancy as a cause of miscarriage, stillbirth, premature birth, low birth weight, placental problems, and sudden infant death syndrome. The organization reports that children born to mothers who smoked during pregnancy face increased risks of developmental problems, respiratory infections, and future tobacco use.

Secondhand smoke exposure creates what WHO calls “involuntary smoking”—non-smokers forced to breathe tobacco smoke in their environment. The organization reports that secondhand smoke contains the same toxic and carcinogenic compounds as directly inhaled smoke. Non-smokers exposed to secondhand smoke face increased risks of lung cancer, cardiovascular disease, stroke, and respiratory infections. Children exposed to secondhand smoke suffer more frequent and severe asthma attacks, respiratory infections, ear infections, and sudden infant death syndrome.

Long-term quality of life impacts extend beyond specific diagnoses. WHO documents that tobacco users experience: reduced physical fitness and exercise tolerance, premature aging of skin, yellowing of teeth and fingers, persistent bad breath, reduced sense of taste and smell, increased susceptibility to infections, slower wound healing, and earlier onset of age-related diseases. These impacts accumulate over years of use, progressively degrading health and functioning.

Economic harms operate at individual, household, and societal levels. WHO reports that tobacco users spend significant proportions of household income on tobacco products—money that could otherwise purchase food, education, or healthcare. Similar to economic analyses of industrial production impacts, the costs include direct expenditures on tobacco, healthcare costs for treating tobacco-related diseases, productivity losses from illness and premature death, and household impoverishment when breadwinners become disabled or die.

The gradient of harm follows a dose-response relationship. WHO emphasizes that while all tobacco use is harmful, greater consumption and longer duration of use increase risks. However, the organization stresses a critical point: even light or occasional smoking carries significant health risks. There is no safe level of tobacco exposure.

Treatment or Health Response — WHO’s Current Approaches

WHO reports that current treatment approaches for tobacco dependence focus on two complementary strategies: behavioral support and pharmacological interventions. The organization emphasizes that combination therapy—using both approaches together—produces the highest quit rates.

Behavioral interventions encompass multiple modalities. WHO documents that brief advice from healthcare providers (even as short as 3 minutes) significantly increases quit rates. More intensive counseling—individual or group—provides additional benefit. Behavioral support helps users identify triggers, develop coping strategies, manage withdrawal symptoms, and prevent relapse.

Pharmacological treatments approved by WHO include nicotine replacement therapy (NRT) available as patches, gum, lozenges, nasal spray, or inhalers that deliver nicotine without the thousands of toxic chemicals in tobacco smoke. The organization notes that NRT approximately doubles quit rates compared to attempting to quit without assistance. Prescription medications—varenicline and bupropion—work through different mechanisms to reduce cravings and withdrawal symptoms. WHO reports that these medications increase quit success rates by 50-100%.

Access to cessation support varies dramatically by country income level. WHO’s framework on treatment access shows that high-income countries typically offer quitlines, cessation clinics, coverage of cessation medications through insurance, and integration of tobacco treatment into primary care. But in low- and middle-income countries—where 80% of tobacco users live—cessation support remains largely unavailable.

Barriers to treatment access identified by WHO include: lack of trained healthcare providers in tobacco cessation counseling, high out-of-pocket costs for medications (NRT can be prohibitively expensive in low-income settings), limited awareness that effective treatments exist, stigma associated with seeking help for addiction, and tobacco industry interference that opposes public funding of cessation services.

Regional differences in treatment approaches reflect resource availability and policy priorities. Countries that have made tobacco control a priority—like Brazil, Turkey, and Uruguay—provide free or subsidized cessation support as part of comprehensive tobacco control programs. But WHO notes that most countries underinvest in cessation services relative to the disease burden.

The organization identifies a fundamental treatment gap: only a small percentage of tobacco users who want to quit have access to evidence-based cessation support. CDC’s Global Tobacco Surveillance System data reveals that while many smokers express desire to quit, the majority attempt to do so without any assistance—resulting in quit rates of less than 5% annually. With behavioral and pharmacological support, quit rates can reach 25-30%.

WHO’s treatment framework also addresses prevention of initiation as a critical intervention. The organization emphasizes that helping young people never start using tobacco is far more effective and cost-efficient than treating established addiction. Prevention strategies include: comprehensive tobacco control policies, protection of youth from tobacco marketing, enforcement of age restrictions on sales, smoke-free environments that denormalize tobacco use, and education about tobacco harms.

Healthcare system integration represents an underutilized opportunity WHO has identified. The organization advocates for systematically assessing and documenting tobacco use in all patient encounters, advising all tobacco users to quit, assisting those ready to quit with counseling and medication, and arranging follow-up support. This “AAAA” model (Ask, Advise, Assist, Arrange) could dramatically increase the number of users receiving evidence-based treatment if widely implemented.

Prevention & WHO Strategies — Public Health Policy Framework

WHO’s prevention framework centers on the MPOWER package—six evidence-based demand reduction measures that the organization identifies as the most cost-effective tobacco control interventions:

Monitor tobacco use and prevention policies through systematic surveillance. WHO emphasizes that countries need robust data on tobacco use prevalence, patterns, and trends to design effective responses and track progress.

Protect people from tobacco smoke through comprehensive smoke-free laws. The organization reports that since 2005, at least 79 countries have enacted comprehensive smoke-free legislation covering all indoor public places, indoor workplaces, and public transport. WHO notes that smoke-free laws protect non-smokers from secondhand smoke, denormalize tobacco use, and motivate smokers to quit.

Offer help to quit tobacco use by providing accessible, affordable cessation support. WHO’s framework calls for establishing toll-free quitlines, training healthcare providers, subsidizing cessation medications, and integrating tobacco treatment into primary healthcare.

Warn about the dangers of tobacco through large pictorial health warnings on packaging and anti-tobacco mass media campaigns. WHO reports that since 2005, at least 110 countries and jurisdictions have implemented pictorial warnings covering at least 50% of tobacco packaging. The organization’s evidence shows that graphic warnings inform consumers about health risks, motivate quit attempts, and deter youth initiation.

Enforce bans on tobacco advertising, promotion, and sponsorship. WHO documents that since 2005, at least 68 countries have passed comprehensive bans. The organization emphasizes that partial bans are ineffective—tobacco companies simply shift marketing to unrestricted channels. Only complete bans across all media effectively reduce exposure to pro-tobacco messages.

Raise taxes on tobacco products. WHO identifies taxation as the single most effective and cost-effective tobacco control measure. The organization recommends that excise taxes constitute at least 70% of retail price. Research cited in the 2024 Tobacconomics Cigarette Tax Scorecard found that the global average cigarette tax score dropped to 1.99 out of 5.00 points in 2022, and only 68 of 170 countries scored 2.50 or higher. WHO notes that higher prices reduce consumption, particularly among youth and low-income users, while generating government revenue.

Beyond MPOWER, WHO’s prevention architecture includes the Framework Convention on Tobacco Control (WHO FCTC)—the first treaty negotiated under WHO auspices. Adopted by the World Health Assembly on May 21, 2003, and entering force on February 27, 2005, the FCTC has been ratified by 182 countries covering over 90% of the world’s population, making it one of the most rapidly and widely embraced treaties in UN history.

The FCTC commits parties to specific tobacco control measures. Article 5.3—perhaps the most critical provision—requires parties to protect public health policies from commercial and other vested interests of the tobacco industry. WHO documents that this article addresses the fundamental conflict between industry interests (profit from addiction) and public health (preventing disease and death).

Other key FCTC articles include: Article 6 on price and tax measures, Article 8 requiring protection from secondhand smoke, Article 11 mandating large health warnings on packaging, Articles 12-13 on education and advertising bans, Article 14 on cessation support, and Articles 15-17 on supply reduction measures including illicit trade control.

WHO established the Protocol to Eliminate Illicit Trade in Tobacco Products as the first protocol to the FCTC. The organization reports that approximately 1 in every 10 cigarettes consumed globally is illicit—depriving governments of tax revenue while making tobacco cheaper and more accessible. The Protocol entered into force in 2018 and establishes a global tracking and tracing system, controls on tobacco supply chain, criminalization of illicit trade, and international cooperation.

Recent WHO initiatives include expanding tobacco control efforts in the Eastern Mediterranean Region, where tobacco control initiatives documented by WHO EMRO protect billions through comprehensive policy implementation. The organization has also intensified focus on novel and emerging products—heated tobacco products, e-cigarettes, nicotine pouches—that industry markets as “reduced risk” despite containing addictive nicotine and serving as gateways to combustible tobacco use.

WHO’s Global Efforts — Recent Initiatives and Editorial Analysis

WHO’s tenth Conference of the Parties (COP10) to the Framework Convention on Tobacco Control convened in February 2024 in Panama City, bringing together representatives from 182 treaty parties. The meeting reviewed progress, addressed emerging challenges, and set new priorities for tobacco control implementation.

But here’s what the meeting outcomes reveal about WHO’s ongoing struggle: despite the FCTC being one of the most widely ratified treaties in history, enforcement remains weak and industry interference continues to undermine progress. The treaty lacks meaningful sanctions for non-compliance. Countries sign and ratify, then fail to implement key provisions, with no consequences beyond diplomatic pressure.

WHO’s January 2024 global trends report documented both successes and failures. Yes, 150 countries are reducing tobacco use. But only 56 countries (down from 60 three years prior) will achieve the 30% reduction target by 2025. Six countries saw tobacco use increase. WHO attributes stalled progress to weakened protection of health policy from tobacco industry interference.

The scale of industry interference is staggering. Tobacco companies spend over $8 billion annually on marketing—dwarfing WHO’s entire tobacco control budget. They employ armies of lawyers and lobbyists to weaken regulations, challenge tobacco control laws in court, threaten trade disputes, make political donations, establish front groups posing as independent organizations, and fund research designed to create doubt about tobacco harms.

WHO’s Article 5.3 guidelines explicitly require parties to prevent industry participation in policy-making, reject partnerships or non-binding agreements with the tobacco industry, denormalize industry activities, require transparency in industry interactions, and regulate activities described as “socially responsible” that actually rehabilitate industry reputation. But implementation remains spotty. Countries routinely violate these guidelines, meeting with industry representatives, accepting industry-funded research, and allowing industry presence in policy discussions.

PAHO’s May 2024 needs assessment for FCTC implementation in The Bahamas illustrates challenges even in countries that have ratified the treaty. The Bahamas made some progress in surveillance, cessation support, and taxation. But significant work remains to create comprehensive smoke-free environments, implement effective advertising bans, and strengthen enforcement of sales restrictions to minors. If a small island nation with relatively strong governance struggles to implement the FCTC, what chance do larger countries with weaker institutions have?

The November 2024 meeting of WHO FCTC Knowledge Hubs in Bangkok revealed ongoing efforts to build country capacity for treaty implementation. These Hubs provide technical assistance, evidence synthesis, and knowledge sharing across nine WHO regions. But the Knowledge Hubs operate with limited resources, and their reach remains insufficient to support all 182 parties effectively.

WHO’s protocol on illicit trade entered force in 2018 but has been ratified by only a fraction of FCTC parties. This undermines effectiveness—illicit trade networks operate across borders, and protocols work only when implemented globally. Countries lacking capacity to implement tracking and tracing systems or unwilling to criminalize illicit trade create holes in the system that smugglers exploit.

The organization’s recent emphasis on protecting children from tobacco industry interference—theme of World No Tobacco Day 2024—addresses a critical vulnerability. Children and adolescents who use e-cigarettes at least double their chance of smoking cigarettes later in life. Yet tobacco companies aggressively market flavored products, use social media influencers, and design packaging that appeals to youth. WHO has issued guidelines on flavor bans, marketing restrictions, and point-of-sale regulations, but implementation lags.

What explains the gap between WHO’s technical guidance and on-the-ground reality? Several factors emerge:

Resource constraints limit WHO’s ability to support implementation. The organization can develop evidence-based policies, but countries need funding and technical assistance to enact and enforce them. WHO’s tobacco control budget pales compared to the $8 billion tobacco companies spend undermining those same policies.

Political will varies dramatically by country. Some nations—Uruguay, Thailand, Australia—treat tobacco control as a priority and resist industry interference. Others prioritize tobacco industry economic interests (jobs, tax revenue) over public health, or lack political capital to challenge powerful industry lobbying.

Corruption enables industry influence. In countries where tobacco companies can buy political access through campaign donations or outright bribes, public health officials fighting for strong policies face insurmountable obstacles.

Litigation threats deter action. Tobacco companies challenge strong regulations using international trade and investment agreements, threatening costly legal battles that frighten resource-poor countries away from comprehensive policies.

Surveillance gaps prevent accurate assessment. WHO’s trends data relies on country reporting, which varies in quality and completeness. Many countries lack capacity to conduct representative surveys, making true disease burden unknown.

What should WHO do differently? Several opportunities exist for more aggressive action:

First, name and shame non-compliant parties. The FCTC implementation database tracks country progress on specific articles. WHO could publish annual rankings identifying best and worst performers, creating peer pressure for improvement.

Second, establish technical assistance funds to help low-income countries implement the FCTC. Current Knowledge Hubs provide guidance but not implementation support. Countries need financial resources to establish enforcement infrastructure, train personnel, conduct surveillance, and fund cessation programs.

Third, coordinate legal defense funds to support countries facing tobacco industry litigation. When Uruguay and Australia faced challenges to plain packaging laws, they ultimately won—but at great cost. A pooled defense fund could help more countries resist industry intimidation.

Fourth, strengthen protocols against illicit trade by incentivizing ratification and providing implementation support. The protocol requires sophisticated tracking systems beyond many countries’ current capacity. WHO could help build those systems.

Fifth, expand surveillance to cover novel products. Current surveys often capture only traditional tobacco, missing e-cigarettes, heated tobacco products, and nicotine pouches. WHO needs data on these products to inform policy responses.

The fundamental question is whether WHO’s framework convention approach can succeed against an industry whose profits depend on addiction, disease, and death. Treaties work when parties have shared interests in compliance. But tobacco companies benefit from non-compliance and actively work to undermine implementation.

Perhaps WHO needs to shift from cooperative engagement to adversarial stance—openly acknowledging that industry interests are fundamentally opposed to public health and designing enforcement mechanisms that don’t rely on good faith. This could include trade sanctions against countries enabling tobacco industry interference, support for litigation against companies for deceptive practices, and advocacy for criminal liability for executives who knowingly market deadly products.

The stakes couldn’t be higher. Eight million people die annually from tobacco. Without dramatic acceleration in tobacco control implementation, WHO estimates that tobacco will kill 1 billion people this century. The Framework Convention provides the roadmap. Whether it can muster the political will and enforcement capacity to follow that roadmap determines whether those billion deaths are inevitable or preventable.

Frequently Asked Questions

---

Sources

1. World Health Organization. Tobacco fact sheet. June 25, 2025. https://www.who.int/news-room/fact-sheets/detail/tobacco
2. United Nations News. Tobacco use declining despite industry interference: WHO. January 16, 2024. https://news.un.org/en/story/2024/01/1145552
3. Centers for Disease Control and Prevention. Global Tobacco Surveillance System. March 11, 2025. https://www.cdc.gov/tobacco/global/index.htm
4. Pan American Health Organization. Tobacco control. https://www.paho.org/en/topics/tobacco-control
5. World Health Organization Europe. WHO Framework Convention on Tobacco Control (WHO FCTC). https://www.who.int/europe/teams/tobacco/who-framework-convention-on-tobacco-control-(who-fctc)

---

DISCLAIMER

This article adapts publicly available information from WHO’s Tobacco page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider.

---

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn